FarrowSure GOLD B (Canada)

This page contains information on FarrowSure GOLD B for veterinary use.
The information provided typically includes the following:
  • FarrowSure GOLD B Indications
  • Warnings and cautions for FarrowSure GOLD B
  • Direction and dosage information for FarrowSure GOLD B

FarrowSure GOLD B

This treatment applies to the following species:
Manufacturer: Zoetis

Parvovirus Vaccine

Killed Virus

Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin

For use in swine only

PRODUCT DESCRIPTION: FarrowSure GOLD B is for vaccination of healthy breeding swine as an aid in preventing reproductive failure caused by porcine parvovirus (PPV), erysipelas caused by Erysipelothrix rhusiopathiae, and leptospirosis caused by Leptospira bratislava, L. canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae and L. pomona. An 18-week duration of immunity following vaccination has been demonstrated against erysipelas. FarrowSure GOLD B is a liquid preparation of porcine parvovirus grown on an established porcine cell line, a serum-free, clarified E. rhusiopathiae culture, and whole cell cultures of the 6 Leptospira serovars identified above. The antigens have been chemically inactivated and adjuvanted with 2 adjuvants, including Amphigen®, to enhance the immune response.

DISEASE DESCRIPTION: PPV and Leptospira are common agents of reproductive loss in swine. While infection with either of these pathogens may produce subclinical disease, infection with PPV during pregnancy may result in fetal resorption, fetal mummification and stillbirths. Infection by Leptospira during the second half of pregnancy may cause abortions and stillbirths; late-term abortions are the most important economic effect of leptospirosis. Leptospirosis caused by any of the serovars represented here cannot be clinically differentiated. Abortions may also occur in sows infected with E. rhusiopathiae during pregnancy.

SAFETY AND EFFICACY: The safety of FarrowSure GOLD B was demonstrated under field conditions in approximately 1,340 sows and gilts receiving single or multiple doses. No serious systemic or allergic reactions were observed following vaccination. Transient local swelling at the injection site was observed in approximately 16% of vaccinated sows and gilts, and approximately 15% of sows exhibited inappetence.

Efficacy of the fractions of FarrowSure GOLD B was demonstrated in controlled challenge-of-immunity and immunogenicity tests. Additionally, duration-of-immunity studies demonstrated that FarrowSure GOLD B protected pigs against E. rhusiopathiae challenge 18 weeks after the second vaccination.

Directions For Use

General Directions: Shake well. Aseptically administer 2 mL intramuscularly.

Primary Vaccination: Healthy swine should receive 2 doses 3-5 weeks apart with the second dose administered 2-4 weeks prior to breeding. Healthy gilts, however, should receive the second dose as near as possible to 14 days prior to breeding.

Revaccination: Revaccination with a single dose is recommended prior to subsequent breedings. Boars should be revaccinated semiannually.

Good animal husbandry and herd health management practices should be employed.

Precautions

Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine.

Do not vaccinate within 21 days before slaughter.

Contains gentamicin as preservative.

Transient injection site swelling and/or inappetence may occur following vaccination.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Technical inquiries should be directed to Pfizer Animal Health Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

® Registered trade-mark of Pfizer Products Inc.; Pfizer Canada Inc., licensee.

™ Trade-mark of Pfizer Products Inc.; Pfizer Canada Inc., licensee.

For veterinary use only

U.S. Veterinary License No. 189

Pfizer Animal Health, Exton, PA 19341, USA

Div. of Pfizer Inc, NY, NY 10017

10-doses

20-mL

5214013

10422800

50-doses

100-mL

5206013

10087200

NAC No.: 11983541

ZOETIS CANADA
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
Order Desk:   800-663-8888
Technical Services Canada:   800-461-0917
Technical Services USA:   800-366-5288
Website:   www.zoetis.ca
Every effort has been made to ensure the accuracy of the FarrowSure GOLD B information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-05-28

(web1)